KR100891568B1 - 나트륨 채널 차단 화합물인 테트로도톡신의 무통 제공 방법 - Google Patents

나트륨 채널 차단 화합물인 테트로도톡신의 무통 제공 방법 Download PDF

Info

Publication number
KR100891568B1
KR100891568B1 KR1020037003723A KR20037003723A KR100891568B1 KR 100891568 B1 KR100891568 B1 KR 100891568B1 KR 1020037003723 A KR1020037003723 A KR 1020037003723A KR 20037003723 A KR20037003723 A KR 20037003723A KR 100891568 B1 KR100891568 B1 KR 100891568B1
Authority
KR
South Korea
Prior art keywords
pain
tetrodotoxin
cancer
ttx
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020037003723A
Other languages
English (en)
Korean (ko)
Other versions
KR20030034181A (ko
Inventor
큉빈 동
프랭크 하이콩 슘
Original Assignee
웩스 메디컬 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 웩스 메디컬 리미티드 filed Critical 웩스 메디컬 리미티드
Publication of KR20030034181A publication Critical patent/KR20030034181A/ko
Application granted granted Critical
Publication of KR100891568B1 publication Critical patent/KR100891568B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Laser Surgery Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
KR1020037003723A 2000-09-18 2001-09-11 나트륨 채널 차단 화합물인 테트로도톡신의 무통 제공 방법 Expired - Lifetime KR100891568B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNB001245171A CN1284536C (zh) 2000-09-18 2000-09-18 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
CN00124517.1 2000-09-18
PCT/CN2001/001391 WO2002022129A1 (en) 2000-09-18 2001-09-11 A method of analgesia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020077023825A Division KR20070112864A (ko) 2000-09-18 2001-09-11 나트륨 채널 차단 화합물인 테트로도톡신의 약학적 조성물

Publications (2)

Publication Number Publication Date
KR20030034181A KR20030034181A (ko) 2003-05-01
KR100891568B1 true KR100891568B1 (ko) 2009-04-03

Family

ID=4590472

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020037003723A Expired - Lifetime KR100891568B1 (ko) 2000-09-18 2001-09-11 나트륨 채널 차단 화합물인 테트로도톡신의 무통 제공 방법
KR1020077023825A Withdrawn KR20070112864A (ko) 2000-09-18 2001-09-11 나트륨 채널 차단 화합물인 테트로도톡신의 약학적 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020077023825A Withdrawn KR20070112864A (ko) 2000-09-18 2001-09-11 나트륨 채널 차단 화합물인 테트로도톡신의 약학적 조성물

Country Status (26)

Country Link
US (1) US6407088B1 (https=)
EP (3) EP1563839B1 (https=)
JP (1) JP2004508404A (https=)
KR (2) KR100891568B1 (https=)
CN (1) CN1284536C (https=)
AT (2) ATE447959T1 (https=)
AU (1) AU2002213785A1 (https=)
BG (1) BG107690A (https=)
BR (1) BR0113961A (https=)
CA (1) CA2421562C (https=)
DE (1) DE60140466D1 (https=)
EA (1) EA004870B1 (https=)
EE (1) EE200300106A (https=)
ES (1) ES2435463T3 (https=)
HR (1) HRP20030202A2 (https=)
HU (1) HUP0302677A3 (https=)
IL (1) IL154342A0 (https=)
IS (1) IS6719A (https=)
MX (1) MXPA03002389A (https=)
NO (1) NO323960B1 (https=)
PL (1) PL360616A1 (https=)
SK (1) SK3732003A3 (https=)
UA (1) UA76960C2 (https=)
WO (1) WO2002022129A1 (https=)
YU (1) YU17103A (https=)
ZA (1) ZA200301852B (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ500590A (en) 1997-04-22 2001-11-30 Cocensys Inc Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
CN1236773C (zh) 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
US7119062B1 (en) 2001-02-23 2006-10-10 Neucoll, Inc. Methods and compositions for improved articular surgery using collagen
CN1269482C (zh) 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
CN1203860C (zh) * 2001-06-22 2005-06-01 威克斯医药有限公司 钠离子通道阻断剂和阿司匹林在制备用于对哺乳动物进行协同镇痛的药物中的应用
MXPA04004543A (es) 2001-11-15 2005-03-31 Micro Algae Corp Composiciones farmaceuticas que contienen 3,4-propinoperhidropurinas y sus usos para el bloqueo de la transmision neuronal.
WO2004013637A1 (en) * 2002-08-01 2004-02-12 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 37 (gpr37)
AU2004207010A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
CN1568999A (zh) 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
JP2005154368A (ja) * 2003-11-27 2005-06-16 Teikoku Seiyaku Co Ltd ジソピラミド含有神経因性疼痛の鎮痛剤
JP2007538010A (ja) * 2004-05-07 2007-12-27 ファイトトックス リミテッド フィコトキシンの経皮投与
JP2007536269A (ja) * 2004-05-07 2007-12-13 ファイトトックス リミテッド ゴニオトキシンを用いた創傷の治療方法
US20050282836A1 (en) * 2004-06-22 2005-12-22 Weiyang Lin Solid orally ingestible formulations of tetrodotoxin
US20060034823A1 (en) * 2004-08-13 2006-02-16 Paul Reid Method of production and use of crotoxin as an analgesic
CN100363006C (zh) * 2004-08-20 2008-01-23 厦门朝阳生物工程有限公司 一种戒毒制剂及其制备方法
CN101039674A (zh) * 2004-09-21 2007-09-19 埃斯蒂文博士实验室股份有限公司 河豚毒素及其衍生物用于治疗中枢神经源性神经痛
CN101039675A (zh) * 2004-09-22 2007-09-19 埃斯蒂文博士实验室股份有限公司 河豚毒素及其衍生物用于治疗外周神经源性神经痛
PE20061036A1 (es) * 2005-02-11 2006-11-24 Esteve Labor Dr Bloqueadores del canal de sodio, tetrodotoxina o saxitoxina, como agentes para el tratamiento de la dependencia de nicotina
EP1714655A1 (en) * 2005-04-22 2006-10-25 Laboratorios Del Dr. Esteve, S.A. Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
EP1690541A1 (en) * 2005-02-11 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Use of a sodium channel blocker and their analogues for the treatment of nicotine dependency
EP1702627A1 (en) * 2005-03-18 2006-09-20 Laboratorios Del Dr. Esteve, S.A. Analgesic combination of sodium channel blockers with opioid antagonists
WO2007025212A2 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
US20100048592A1 (en) * 2005-08-25 2010-02-25 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the management of musculoskeletal pain
US20070148159A1 (en) * 2005-12-22 2007-06-28 Reid Paul F Use of crotoxin as an analgesic - CIP
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
EP1844781A1 (en) 2006-02-22 2007-10-17 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of preterm labor
EP1844782A1 (en) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel subunit Nav1.6
ES2691411T3 (es) 2006-03-27 2018-11-27 Wex Medical Limited Uso de bloqueadores de los canales de sodio para el tratamiento del dolor neuropático que se desarrolla como consecuencia de la quimioterapia
EP1844783A1 (en) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel - subunit Nav1.6
WO2007110220A1 (en) * 2006-03-27 2007-10-04 Wex Pharmaceuticals Inc. USE OF 4,9-ANHYDRO-TETRODOTOXIN FOR THE TREATMENT OF DISEASES RELATED TO THE VOLTAGE-GATED SODIUM CHANNEL α SUBUNIT NAV 1.6
CN100438873C (zh) * 2006-06-26 2008-12-03 黄致强 将河鲀毒素作为镇痛药的耐受抑制剂在制备复方镇痛制剂中的应用
EP1882692A1 (en) * 2006-07-28 2008-01-30 Wex Pharmaceuticals Inc. Dimethano-[1,3]dioxocino[6,5-D]pyrimidine-spiro derivatives of tetrodotoxin, process for their synthesis and uses thereof in the treatment of pain
CN101730467A (zh) * 2007-07-06 2010-06-09 努恩治疗学股份有限公司 神经病性疼痛的治疗
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US8957207B2 (en) 2009-03-24 2015-02-17 Proteus S.A. Methods for producing phycotoxins
US20120034296A1 (en) * 2009-04-08 2012-02-09 Massachusetts Institute Of Technology Prolonged duration local anesthesia with minimal toxicity
JP6112867B2 (ja) * 2010-02-10 2017-04-12 ファイトトックス リミテッドＰｈｙｔｏｔｏｘ Ｌｉｍｉｔｅｄ サキシトキシン誘導体での触覚の喪失の処置
US20120310140A1 (en) 2010-12-01 2012-12-06 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
MX2015010749A (es) 2013-03-14 2015-11-30 Regeneron Pharma Anticuerpos humanos para nav1.7.
RS58750B1 (sr) * 2013-03-15 2019-06-28 Childrens Medical Ct Corp Kombinovane formulacije neosaksitoksina za produženu lokalnu anesteziju
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN107198689A (zh) * 2017-07-11 2017-09-26 东新皓特（北京）生化科技有限公司 用于治疗疼痛病症的河豚毒素药物组合物及外用药
CN117202912A (zh) 2021-04-23 2023-12-08 威克斯药业有限公司 河豚毒素液体制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0750909A1 (en) * 1994-03-17 1997-01-02 Nanning Maple Leaf Pharmaceutical Co., Ltd. The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence
WO1998051290A2 (en) * 1997-05-16 1998-11-19 Children's Medical Center Corporation Local anesthetic formulations comprising a site 1 sodium channel blocker combined with a second active agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029793A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
CN1072486C (zh) * 1996-09-24 2001-10-10 王维国 用于戒毒、镇痛的药剂及其制法
WO1998043619A2 (en) * 1997-04-02 1998-10-08 The Regents Of The University Of California Method of local anesthesia
CN1236773C (zh) * 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0750909A1 (en) * 1994-03-17 1997-01-02 Nanning Maple Leaf Pharmaceutical Co., Ltd. The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence
WO1998051290A2 (en) * 1997-05-16 1998-11-19 Children's Medical Center Corporation Local anesthetic formulations comprising a site 1 sodium channel blocker combined with a second active agent

Also Published As

Publication number Publication date
BG107690A (bg) 2004-01-30
ES2435463T3 (es) 2013-12-19
SK3732003A3 (sk) 2005-05-05
DE60140466D1 (de) 2009-12-24
NO323960B1 (no) 2007-07-23
EP1320369B1 (en) 2009-11-11
ATE542534T1 (de) 2012-02-15
EA200300172A1 (ru) 2003-12-25
WO2002022129A1 (en) 2002-03-21
KR20070112864A (ko) 2007-11-27
EP1320369A1 (en) 2003-06-25
IL154342A0 (en) 2003-09-17
EP1320369A4 (en) 2003-07-02
ATE447959T1 (de) 2009-11-15
NO20030915L (no) 2003-04-25
EA004870B1 (ru) 2004-08-26
MXPA03002389A (es) 2004-03-12
YU17103A (sh) 2006-03-03
CN1284536C (zh) 2006-11-15
PL360616A1 (en) 2004-09-20
US6407088B1 (en) 2002-06-18
CN1356104A (zh) 2002-07-03
KR20030034181A (ko) 2003-05-01
ZA200301852B (en) 2004-06-21
EP2298306A1 (en) 2011-03-23
HRP20030202A2 (en) 2005-02-28
IS6719A (is) 2003-02-14
UA76960C2 (en) 2006-10-16
CA2421562A1 (en) 2002-03-21
EP1563839A1 (en) 2005-08-17
CA2421562C (en) 2011-05-24
HUP0302677A2 (hu) 2003-11-28
EP2298306B1 (en) 2013-09-11
AU2002213785A1 (en) 2002-03-26
NO20030915D0 (no) 2003-02-27
JP2004508404A (ja) 2004-03-18
HUP0302677A3 (en) 2005-01-28
EP1563839B1 (en) 2012-01-25
EE200300106A (et) 2005-04-15
BR0113961A (pt) 2004-01-13

Similar Documents

Publication Publication Date Title
KR100891568B1 (ko) 나트륨 채널 차단 화합물인 테트로도톡신의 무통 제공 방법
Giacoppo et al. Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation
JP6771512B2 (ja) 抗不安薬組成物、製剤および使用方法
EP3534925A2 (en) Combination therapies with cannabis plant extract
KR20150120479A (ko) 니트라이트의 약제학적 제형 및 이의 용도
US20150111852A1 (en) 1-Di(sec-butyl)-phosphinoyl-pentane (dapa-2-5) as a topical agent...
EP2138174A1 (en) Pharmaceutical composition in the form of a sublingual tablet consisting of a non-steroidal anti-inflammatory agent and an opiate analgesic for pain management
AU2005287511A1 (en) Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain
JP2024502466A (ja) 抗発作治療薬の急速な送達のための方法および組成物
AU2007200073B2 (en) A Method of Analgesia
JP2022523885A (ja) 疼痛管理のための製剤
CN105030920A (zh) 一种治疗口腔溃疡和喉病的中药组合物
KR20150081345A (ko) 여성 성 기능이상에 대한 브레멜라노타이드 요법
WO2021063387A1 (zh) 伊马替尼及其衍生物的组合物在制备预防、治疗及防治成瘾复吸药物中的应用
AU2015363757A1 (en) Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
EP4422611A1 (en) Methods of treating head and neck cancers with hemp extract
WO2019135363A1 (ja) 腱滑膜病変を主体とした疾患の治療薬
WO2010120203A1 (ru) Применение органических красителей в качестве обезболивающих средств

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20030313

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20041228

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060614

Patent event code: PE09021S01D

AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20070207

Patent event code: PE09021S02D

AMND Amendment
E601 Decision to refuse application
E801 Decision on dismissal of amendment
PE0601 Decision on rejection of patent

Patent event date: 20070822

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20070207

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20060614

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20070822

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20070406

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20061016

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20041228

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20030314

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20070919

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20070822

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20080611

Appeal identifier: 2007101009918

Request date: 20070919

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20071017

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20071017

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20070919

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20070406

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20061016

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20041228

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20030314

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
E801 Decision on dismissal of amendment
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20071116

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20071116

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20071017

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20070406

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20061016

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20041228

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20030314

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20070919

Effective date: 20080611

Free format text: TRIAL NUMBER: 2007101009918; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20070919

Effective date: 20080611

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20080611

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20070919

Decision date: 20080611

Appeal identifier: 2007101009918

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080704

Patent event code: PE09021S01D

GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20081226

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20080613

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20090326

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20090326

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20120302

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20120302

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20130319

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20130319

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20140327

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20140327

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20150312

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20150312

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20160310

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20160310

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20170317

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20170317

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20180309

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20180309

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20190314

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20190314

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20200313

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20200313

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20210226

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20210226

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term